About 109,131 shares traded. Piper Jaffray upgraded Pacific Biosciences of California (NASDAQ:PACB) on Friday, October 23 to "Overweight" rating. The company moved in the past week with shift of 10.73%.

Pacific Biosciences (NASDAQ:PACB)'s trailing twelve month revenues are $96.5 Million, whereas its price to sales ratio for the same period is 3.86. Its down 20.2% from 322,200 shares previously. It has underperformed by 56.51% the S&P500.

Investors sentiment increased to 1.1 in 2016 Q4. Its down 0.06, from 1.23 in 2016Q3.

Oracle Investment Management Inc holds 3.48% of its portfolio in Pacific Biosciences of California for 5.52 million shares. 34 funds opened positions while 92 raised stakes. Allianz Asset Mgmt Ag stated it has 418,075 shares or 0% of all its holdings. Hsbc Public Limited Co has 13,836 shares. Swiss Retail Bank invested in 138,646 shares or 0% of the stock.

The company has mean EPS estimate of -0.2 reported by 6 number of analyst for the quarter ending Current Qtr.(Jun2017). Legal & General Grp Inc Public Ltd Liability Corp, United Kingdom-based fund reported 19,469 shares. Geduld E E accumulated 85,000 shares. Lord Abbett & Co Limited Liability Co invested in 0.03% or 2.69 million shares. SG Americas Securities LLC owned about 0.10% of Pacific Biosciences of California worth $464,000 as of its most recent filing with the SEC. Walleye Trading Limited Com holds 0% or 21,320 shares in its portfolio. Moreover, Prelude Lc has 0% invested in Pacific Biosciences of California (NASDAQ:PACB). Ameriprise Fincl invested 0% in Pacific Biosciences of California (NASDAQ:PACB). Pacific Biosciences of California's revenue for the quarter was up 30.4% compared to the same quarter past year.

Poulter savours return to Birkdale
When I missed my drives I missed them in locations where I could still hit the greens. "You look at how it was at Erin Hills". Open , he made the decision to head to Las Vegas for a celebratory get-together with some of his friends.

Pacific Biosciences of California, Inc. designs, develops and makes sequencing systems to help scientists resolve genetically complex problems. The company's market cap is $321.81 million. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. It now has negative earnings. The Company's Single Molecule, Real-Time technology enables single molecule, real-time detection of biological processes. For the current year the company's revenue estimates are $107.43 Million compared to low analyst estimates of $105.8 Million and high estimates of $110 Million according to the prediction of 6 analysts. For the next year, analysts forecast that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.74) to ($0.65).

Pacific Biosciences of California, Inc. has a consensus outperform rating from 6 Wall Street analysts, and the number of shares now sold short amount to at least 13.33% of shares outstanding. Therefore 60% are positive. ValuEngine cut Pacific Biosciences of California from a "sell" rating to a "strong sell" rating in a report on Tuesday, June 13th. Finally, Cantor Fitzgerald set a $8.00 price target on Pacific Biosciences of California and gave the company a "buy" rating in a report on Thursday, April 27th. As per Thursday, February 4, the company rating was downgraded by Piper Jaffray. Cantor Fitzgerald initiated it with "Buy" rating and $9 target in Thursday, August 27 report.

First Analysis "Initiates Coverage on" Pacific Biosciences (NASDAQ:PACB) in a research note issued to investors on 4/15/16 to Overweight. The firm has "Buy" rating by Maxim Group given on Thursday, August 27. (PACB) stock moved with shift of 1.46% in the past week. The stock of Pacific Biosciences of California (NASDAQ:PACB) earned "Buy" rating by Cantor Fitzgerald on Monday, January 4. The company has market cap of $47.31 million. The Company's platform enables digital marketers to manage performance of their online advertising campaigns.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.